ACP 319 - ACADIA Pharmaceuticals
Alternative Names: ACP-319 - ACADIA Pharmaceuticals; Muscarinic M1 receptor modulator - ACADIA Pharmaceuticals/Vanderbilt UniversityLatest Information Update: 12 Aug 2022
Price :
$50 *
At a glance
- Originator Vanderbilt University
- Developer ACADIA Pharmaceuticals
- Class Antipsychotics; Nootropics
- Mechanism of Action Muscarinic M1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cognition disorders; Schizophrenia